|
Jul 15
|
EU Commission Approves Vertex Pharmaceutical’s (VRTX) Cystic Fibrosis Treatment
|
|
Jul 15
|
Vertex and NHS England agree reimbursement for Alyftrek
|
|
Jul 15
|
Vertex Pharmaceuticals And 2 Other Stocks That May Be Trading Below Their Estimated Value
|
|
Jul 15
|
Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug
|
|
Jul 14
|
Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis
|
|
Jul 14
|
Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain
|
|
Jul 14
|
My 3 Top Stocks to Buy in a Market That's Highly Volatile (Again)
|
|
Jul 10
|
Suzetrigine: a new era in non-opioid pain relief
|
|
Jul 9
|
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
|
|
Jul 8
|
Vertex to Announce Second Quarter 2025 Financial Results on August 4th
|
|
Jul 8
|
Vertex Protocol Team to Join Ink Foundation, Build New DeFi Primitives on Ink Layer-2
|
|
Jul 8
|
Do You Believe in the Upside Potential of Vertex Pharmaceuticals (VRTX)?
|
|
Jul 7
|
Intellia Gains 29.8% in a Month: How Should You Play the Stock?
|
|
Jul 7
|
Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs
|
|
Jul 5
|
The Best Stocks to Invest $1,000 In Right Now
|
|
Jul 4
|
Vertex reports long-term results for Casgevy in sickle cell and thalassaemia
|
|
Jul 2
|
Vertex Pharmaceuticals (NasdaqGS:VRTX) Secures EU Approval for New CF Treatment Access
|
|
Jul 2
|
Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek
|
|
Jul 2
|
Vertex wins European approval for Alyftrek, bolstering cystic fibrosis stronghold
|
|
Jul 1
|
Vertex Announces European Commission Approval of ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis
|